Genetic Risk and Gynecologic Cancers
Section snippets
HBOC syndrome
HBOC syndrome is caused by mutations in the BRCA1 or BRCA2 genes, which were first identified and cloned in the early 1990s.4, 5 The prevalence of mutations in BRCA1 and BRCA2 among the general population has been estimated to be as high as 1 in 400.6 However, this varies among different populations. In certain populations that have undergone a period of relative isolation, founder mutations in BRCA1 and BRCA2 have been identified. For example, Ashkenazi Jews have a prevalence of approximately
Lynch syndrome
Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, accounts for most inherited endometrial cancer cases. The original family was described in 1913 by Aldred Warthin, although the syndrome was not characterized until the 1960s and 1970s.78, 79, 80 Since that time, Lynch syndrome has been recognized as an inherited mutation in one of the DNA mismatch repair genes (MLH1, MSH2, MSH6, or PMS2). The prevalence of these mutations in the general population is
Other syndromes
Several other rare hereditary cancer syndromes have gynecologic manifestations, including Peutz-Jeghers syndrome (PJS), Cowden syndrome (CS), and Li-Fraumeni syndrome (LFS). Given their rarity, there are few data regarding screening, prognosis, and treatment.
Pigmented lesions on the lips and buccal mucosa, as well as increased risk for tumors and malignancies at multiple sites, including the breast, gastrointestinal system, and the gynecologic organs, characterize PJS. PJS results from germline
Summary
Although most gynecologic malignancies are sporadic, hereditary cancer syndromes cause a substantial portion of these cancers. Given that the diagnosis of these syndromes has prognostic and therapeutic implications for the patient, as well as preventive implications for her family members, genetic testing is now an accepted part of the management of the patient who has gynecologic cancer.
References (115)
- et al.
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions
Gynecol Oncol
(2007) - et al.
Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer
Gynecol Oncol
(2011) - et al.
Pathologic findings in prophylactic oophorectomy specimens in high-risk women
Gynecol Oncol
(2002) - et al.
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
Gynecol Oncol
(2006) - et al.
The incidence of primary fallopian tube cancer in the United States
Gynecol Oncol
(2007) - et al.
Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis
Gynecol Oncol
(2001) - et al.
Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations
Gynecol Oncol
(2011) - et al.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Lancet
(2010) - et al.
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
Am J Hum Genet
(2001) - et al.
Population attributes affecting the prevalence of BRCA mutation carriers in epithelial ovarian cancer cases in Israel
Gynecol Oncol
(2003)
Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians
Am J Prev Med
Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer
Genet Med
Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer
Genet Med
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study
Lancet Oncol
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis
Eur J Cancer
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations
Gynecol Oncol
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study
Lancet Oncol
Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy
Gynecol Oncol
Risk of endometrial carcinoma associated with BRCA mutation
Gynecol Oncol
Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ-line mutation of BRCA1 or 2 genes? Rationale and preliminary development
Gynecol Oncol
The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer
Gynecol Oncol
Simultaneously detected endometrial and ovarian carcinomas–a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study
Gynecol Oncol
Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance
Gynecol Oncol
A population-based study of endometrial cancer and familial risk in younger women. Cancer and hormone study group
Cancer Epidemiol Biomarkers Prev
Clinical relevance of hereditary ovarian cancer
Cancer statistics, 2011. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths
CA Cancer J Clin
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
Science
Identification of the breast cancer susceptibility gene BRCA2
Nature
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group
Br J Cancer
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
N Engl J Med
Epithelial ovarian cancer
Hereditary cancer predisposition syndromes
J Clin Oncol
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome
Obstet Gynecol
BRCA1 and BRCA2 hereditary breast and ovarian cancer
Breast cancer risk among male BRCA1 and BRCA2 mutation carriers
J Natl Cancer Inst
Cancer risks in BRCA2 mutation carriers
J Natl Cancer Inst
Cancer incidence in BRCA1 mutation carriers
J Natl Cancer Inst
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: A kin-cohort study in Ontario, Canada
J Natl Cancer Inst
Histopathologic features of genetically determined ovarian cancer
Int J Gynecol Pathol
Pathology of BRCA-associated ovarian cancers, including occult cancers
Clinical genetics of gynecologic cancer
Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1
N Engl J Med
Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry
Int J Gynecol Pathol
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases
Cancer
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction
J Clin Oncol
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome
Am J Surg Pathol
Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy
J Clin Oncol
Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy
J Clin Oncol
Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status
Am J Surg Pathol
Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesis
Cancer Prev Res (Phila)
Cited by (4)
Gynecologic cancers and solid organ transplantation
2019, American Journal of TransplantationCancers Arising in the Ovary
2014, Abeloff's Clinical Oncology: Fifth EditionPediatric, adolescent, and young adult breast and reproductive tumors
2023, Pediatric Blood and CancerNGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU
2021, Archives of Gynecology and Obstetrics